LIVIVO - Search results -

Search results

Result 1 - 10 of total 62

Search options

Article ; Online: Gynecologic Adnexal Tumors and Tumor-Like Lesions in Children and Adolescents: Experience at a Cancer Center.

Costa, João / Alves, Sara / Silva, Fernanda / Leite, Filipa / Bartosch, Carla

International journal of surgical pathology

2024 , Page(s) 10668969241232698

Abstract: Introduction. ...

Abstract	Introduction.
Language	English
Publishing date	2024-02-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	1336393-1
ISSN	1940-2465 ; 1066-8969
ISSN (online)	1940-2465
ISSN	1066-8969
DOI	10.1177/10668969241232698
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4500: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Expert pathology for GTD: towards an international multidisciplinary team meeting (MDT).

Kaur, Baljeet / Nadal, Alfons / Bartosch, Carla / Rougemont, Anne-Laure

Gynecologic and obstetric investigation

2024

Abstract: Background: Gestational trophoblastic disease, comprising hydatidiform moles and gestational trophoblastic tumours, is extremely rare. Exact diagnosis is crucial to indicate the appropriate treatment and to prevent complications. The scarcity and ... ...

Abstract	Background: Gestational trophoblastic disease, comprising hydatidiform moles and gestational trophoblastic tumours, is extremely rare. Exact diagnosis is crucial to indicate the appropriate treatment and to prevent complications. The scarcity and variability in the number of cases available for reporting, lack of specialized training in GTD and non-existence of refresher courses available implies that the pathologist dealing with these rare and at times extremely challenging cases are not completely confident in their diagnosis. Objectives: To explores the benefits of implementation of an international multidisciplinary conference (virtual) to aid diagnosis of difficult cases and support clinical management of GTD. Methods: A short survey was circulated to all 46 members of the EOTTD pathology and genetics working party, and further spread to other colleagues who practice GTD. This showed that the pathologists and geneticists working with GTD patients do not feel adequately supported and equipped with dealing with these rare diseases. Outcome: Virtual cross-border MDTs were initiated in April 2022, bringing together participants from 11 European countries on a bi-yearly basis. Mean numbers of 3 patients are discussed during the MDTs followed by 3-4 QA cases. A participant survey was conducted at the end of virtual meeting with an average satisfaction rate of 9.5. The pathologists felt supported and benefited from networking and clinical collaboration. Conclusions and outlook: This international multidisciplinary team meeting (MDT) continues to provide support in managing the uncertainty with difficult and rare cases and enhances the pathologists training and experience. The frequency of meetings and the number of cases discussed per meeting will be increased in 2023 given the positive response. This will empower individuals and organisations to work together and improve diagnosis and the prognosis for these young patients.
Language	English
Publishing date	2024-01-08
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	800003-7
ISSN	1423-002X ; 0378-7346
ISSN (online)	1423-002X
ISSN	0378-7346
DOI	10.1159/000536028
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 688: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.

Nunes, Mariana / Bartosch, Carla / Abreu, Miguel Henriques / Richardson, Alan / Almeida, Raquel / Ricardo, Sara

Cells

2024 Volume 13, Issue 9

Abstract: Ovarian cancer is a highly lethal form of gynecological cancer. This disease often goes undetected until advanced stages, resulting in high morbidity and mortality rates. Unfortunately, many patients experience relapse and succumb to the disease due to ... ...

Abstract	Ovarian cancer is a highly lethal form of gynecological cancer. This disease often goes undetected until advanced stages, resulting in high morbidity and mortality rates. Unfortunately, many patients experience relapse and succumb to the disease due to the emergence of drug resistance that significantly limits the effectiveness of currently available oncological treatments. Here, we discuss the molecular mechanisms responsible for resistance to carboplatin, paclitaxel, polyadenosine diphosphate ribose polymerase inhibitors, and bevacizumab in ovarian cancer. We present a detailed analysis of the most extensively investigated resistance mechanisms, including drug inactivation, drug target alterations, enhanced drug efflux pumps, increased DNA damage repair capacity, and reduced drug absorption/accumulation. The in-depth understanding of the molecular mechanisms associated with drug resistance is crucial to unveil new biomarkers capable of predicting and monitoring the kinetics during disease progression and discovering new therapeutic targets.
MeSH term(s)	Humans ; Female ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2024-05-04
Publishing country	Switzerland
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells13090786
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Editorial: New molecular approaches to improve gynecological cancer management.

Abreu, Miguel Henriques / Lillsunde-Larsson, Gabriella / Bartosch, Carla / Ricardo, Sara

Frontiers in oncology

2023 Volume 13, Page(s) 1235035

Language	English
Publishing date	2023-06-21
Publishing country	Switzerland
Document type	Editorial
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1235035
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Short tandem repeat analysis: a practical tool to identify specimen mix-ups in the pathology laboratory.

João, David / Cardoso, Sara / Monteiro, Paula / Leal, Conceição / Bartosch, Carla

Virchows Archiv : an international journal of pathology

2023 Volume 483, Issue 4, Page(s) 549–554

Abstract: Despite all precautions in pathology laboratories, contaminations and specimen mix-ups still occur and can negatively impact both patients and institutions. We present two cases in which short tandem repeat (STR) analysis was used to assert the correct ... ...

Abstract	Despite all precautions in pathology laboratories, contaminations and specimen mix-ups still occur and can negatively impact both patients and institutions. We present two cases in which short tandem repeat (STR) analysis was used to assert the correct identity of specimens. The first patient had a biopsy diagnosis of triple negative invasive carcinoma of no special type of the breast. Sample mix-up with another biopsy was suspected, because in her post-chemotherapy mastectomy specimen, a hormone receptor-positive lobular carcinoma was diagnosed. STR analysis displayed a complete common loci profile of the patient's biopsy and mastectomy, supporting that no mix-up occurred. The second patient underwent hysterectomy due to cervix squamous cell carcinoma. A fragment of adenocarcinoma was identified and confirmed by STR profile to be a contaminant. STR analysis is a fast, easy-to-perform, and widely available technique which can clarify contaminations and specimen mix-ups in pathology laboratories.
MeSH term(s)	Female ; Humans ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Laboratories ; Mastectomy ; Microsatellite Repeats/genetics ; Carcinoma, Lobular
Language	English
Publishing date	2023-06-27
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1184867-4
ISSN	1432-2307 ; 0945-6317
ISSN (online)	1432-2307
ISSN	0945-6317
DOI	10.1007/s00428-023-03578-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud III Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Molecular Classification of Endometrial Carcinoma: Protocol for a Cohort Study.

Moreira, Inês / Bartosch, Carla / Teixeira, Manuel / Ferreira, Marta

JMIR research protocols

2022 Volume 11, Issue 8, Page(s) e34461

Abstract: Background: Endometrial carcinoma (EC) is the most common gynecologic malignancy in developed countries and the fourth most frequent in women worldwide. The cornerstone of treatment for EC is surgery. Clinicopathological features are currently used to ... ...

Abstract	Background: Endometrial carcinoma (EC) is the most common gynecologic malignancy in developed countries and the fourth most frequent in women worldwide. The cornerstone of treatment for EC is surgery. Clinicopathological features are currently used to help determine the individual risk of recurrence and the need for adjuvant treatment after surgery. Nonetheless, there is significant interobserver variability in assigning histologic subtype when using a morphological classification, revealing the need for a more unified approach. The Cancer Genome Atlas (TCGA) project identified 4 distinct prognostic EC subtypes based on genomic abnormalities. Surrogate assays including 3 immunohistochemical markers (p53, MSH6, and PMS2) and 1 molecular test (mutation analysis of the exonuclease domain of DNA polymerase epsilon; POLE) allowed the development and validation of a simplified molecular classifier that correlates with the TCGA classification, has prognostic value, and can easily be used in clinical practice. This molecular classification categorizes EC in 4 subtypes: POLE mutated, mismatch repair-deficient, p53 abnormal, and no specific molecular profile. Applying this classification in clinical practice will help tailor adjuvant treatment decisions. Objective: The aim of this study is to retrospectively apply this novel molecular classification to a cohort of patients with EC treated in a comprehensive cancer center, to assess its applicability in clinical practice, to evaluate clinical outcomes by molecular subtypes, and to assess its prognostic value. Methods: In this retrospective cohort study, patients with primary EC diagnosed during and after 2013 and treated or followed at our institution, after definite surgery, will be included. Demographic and clinicopathological data will be obtained from electronic health records and from pathology reports. Laboratory methods will include immunohistochemical study of p53 and mismatch repair proteins, as well as POLE mutational analysis by genetic sequencing. The primary end point is recurrence-free survival and secondary end points are disease-specific survival and overall survival. A descriptive analysis of variables will be carried out. Survival analysis will be performed using the Kaplan-Meier method and the groups will be compared using the log-rank test. Results: This protocol was reviewed and approved by the Instituto Português de Oncologia do Porto, Portugal, ethics committee in October 2021; patient selection from our cancer registry began the same month. A total of 160 patients will be included. This work will present real-life results that will allow a better understanding of the Portuguese EC population and the distribution of the molecular subgroups throughout. We will use these results to understand the prognostic value of this classification in our population and its role in adjuvant therapy decisions. This study is anticipated to conclude in December 2022. Conclusions: This study will provide important information regarding these women's outcomes according to this new molecular classification and will support its use when discussing a patient's need for adjuvant treatment. International registered report identifier (irrid): PRR1-10.2196/34461.
Language	English
Publishing date	2022-08-04
Publishing country	Canada
Document type	Journal Article
ZDB-ID	2719222-2
ISSN	1929-0748
ISSN	1929-0748
DOI	10.2196/34461
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma.

Magalhães, Denise / Bartosch, Carla / Abreu, Miguel H

Cureus

2022 Volume 14, Issue 7, Page(s) e26662

Abstract: Ovarian carcinosarcoma (OCS) is a rare entity with a poor prognosis and without evidence-based therapy. Here, we report the case of a 55-year-old woman with a ... ...

Abstract	Ovarian carcinosarcoma (OCS) is a rare entity with a poor prognosis and without evidence-based therapy. Here, we report the case of a 55-year-old woman with a germline
Language	English
Publishing date	2022-07-08
Publishing country	United States
Document type	Case Reports
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.26662
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Placental site trophoblastic tumour: five challenges of patient clinical management.

Peixinho, Catarina / Almeida, Amélia / Bartosch, Carla / Cruz Pires, Mónica

BMJ case reports

2021 Volume 14, Issue 1

Abstract: Placental site trophoblastic tumour is a rare form of gestational trophoblastic disease accounting for about 1%-2% of all trophoblastic tumours. Diagnosis and management of placental site trophoblastic tumour can be difficult.We report a case of a 30- ... ...

Abstract	Placental site trophoblastic tumour is a rare form of gestational trophoblastic disease accounting for about 1%-2% of all trophoblastic tumours. Diagnosis and management of placental site trophoblastic tumour can be difficult.We report a case of a 30-year-old woman diagnosed with a placental site trophoblastic tumour and identify the challenges in diagnosis and treatment of this rare situation. The presenting sign was abnormal vaginal bleeding that started 3 months after delivery. Image exams revealed an enlarged uterus with a heterogeneous mass, with vesicular pattern, and the increased vascularisation serum human chorionic gonadotropin level was above normal range. The histological diagnosis was achieved through hysteroscopic biopsy. Staging exams revealed pulmonary micronodules. The patient was successfully treated with hysterectomy and chemotherapy. The latest follow-up (37 months after diagnosis) was uneventful, and the patient exhibited no signs of recurrence or metastasis.
MeSH term(s)	Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Chorionic Gonadotropin/blood ; Cisplatin/therapeutic use ; Consolidation Chemotherapy ; Dactinomycin/therapeutic use ; Etoposide/administration & dosage ; Etoposide/therapeutic use ; Female ; Humans ; Hysterectomy ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/drug therapy ; Lung Neoplasms/secondary ; Lymph Node Excision ; Methotrexate/therapeutic use ; Paclitaxel/administration & dosage ; Pregnancy ; Puerperal Disorders/blood ; Puerperal Disorders/diagnostic imaging ; Puerperal Disorders/pathology ; Puerperal Disorders/therapy ; Salpingectomy ; Trophoblastic Tumor, Placental Site/diagnostic imaging ; Trophoblastic Tumor, Placental Site/pathology ; Trophoblastic Tumor, Placental Site/secondary ; Trophoblastic Tumor, Placental Site/therapy ; Uterine Neoplasms/blood ; Uterine Neoplasms/diagnostic imaging ; Uterine Neoplasms/pathology ; Uterine Neoplasms/therapy
Chemical Substances	Chorionic Gonadotropin ; Dactinomycin (1CC1JFE158) ; Etoposide (6PLQ3CP4P3) ; Paclitaxel (P88XT4IS4D) ; Cisplatin (Q20Q21Q62J) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2021-01-28
Publishing country	England
Document type	Case Reports ; Journal Article
ISSN	1757-790X
ISSN (online)	1757-790X
DOI	10.1136/bcr-2020-238994
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.

Lima, Bárbara / Abreu, Miguel Henriques / Sousa, Susana / Bartosch, Carla / Pereira, Deolinda

Gynecologic oncology reports

2022 Volume 40, Page(s) 100942

Abstract: Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is ... ...

Abstract	Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinase (MAPK) pathway plays a significant role in the pathogenesis of these tumours, and about 2 to 20% of LGSOC harbour a BRAF mutation. Here we present a case report of two patients with a BRAF V600E mutation that achieved sustained clinical responses with combination treatment with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).
Language	English
Publishing date	2022-02-23
Publishing country	Netherlands
Document type	Case Reports
ZDB-ID	2818505-5
ISSN	2352-5789
ISSN	2352-5789
DOI	10.1016/j.gore.2022.100942
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.

Nunes, Mariana / Henriques Abreu, Miguel / Bartosch, Carla / Ricardo, Sara

International journal of molecular sciences

2020 Volume 21, Issue 20

Abstract: The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) ... ...

Abstract	The main challenge in ovarian cancer treatment is the management of recurrences. Facing this scenario, therapy selection is based on multiple factors to define the best treatment sequence. Target therapies, such as bevacizumab and polymerase (PARP) inhibitors, improved patient survival. However, despite their achievements, ovarian cancer survival remains poor; these therapeutic options are highly costly and can be associated with potential side effects. Recently, it has been shown that the combination of repurposed, conventional, chemotherapeutic drugs could be an alternative, presenting good patient outcomes with few side effects and low costs for healthcare institutions. The main aim of this review is to strengthen the importance of repurposed drugs as therapeutic alternatives, and to propose an in vitro model to assess the therapeutic value. Herein, we compiled the current knowledge on the most promising non-oncological drugs for ovarian cancer treatment, focusing on statins, metformin, bisphosphonates, ivermectin, itraconazole, and ritonavir. We discuss the primary drug use, anticancer mechanisms, and applicability in ovarian cancer. Finally, we propose the use of these therapies to perform drug efficacy tests in ovarian cancer ex vivo cultures. This personalized testing approach could be crucial to validate the existing evidences supporting the use of repurposed drugs for ovarian cancer treatment.
MeSH term(s)	Diphosphonates/therapeutic use ; Drug Repositioning/methods ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Itraconazole/therapeutic use ; Ivermectin/therapeutic use ; Metformin/therapeutic use ; Neoplasm Recurrence, Local/prevention & control ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Ritonavir/therapeutic use
Chemical Substances	Diphosphonates ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Itraconazole (304NUG5GF4) ; Ivermectin (70288-86-7) ; Metformin (9100L32L2N) ; Ritonavir (O3J8G9O825)
Language	English
Publishing date	2020-10-20
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms21207768
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito